Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Interstitial Lung Abnormalities: later-stage trial registry

1 of 1 indexed Interstitial Lung Abnormalities trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Interstitial Lung Abnormalities: 1 US clinical trial tracked, 1 recruiting.

Interstitial Lung Abnormalities is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Boehringer Ingelheim, running 1 of these trials.

Enrollment posture brief

Registry condition interstitial-lung-abnormalities

OPEN 1 | RECR 100% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Interstitial Lung Abnorm (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Interstitial Lung Abnormalities

Interstitial Lung Abnormalities lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Interstitial Lung Abnormalities on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Interstitial Lung Abnormalities is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 31

Phase Distribution

PhaseTrial count
Phase 3 1

Top Sponsors

Named interventions

Most-linked intervention names on Interstitial Lung Abnormalities records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Nerandomilast Drug
1 trials
Placebo Drug
1 trials

US sites by state

Facility locations filed on Interstitial Lung Abnormalities trials. A trial with sites in several states counts in each.

Virginia 1 trials
Texas 1 trials
Tennessee 1 trials
South Carolina 1 trials
Pennsylvania 1 trials
New York 1 trials
Minnesota 1 trials
Michigan 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Interstitial Lung Abnormalities page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Interstitial Lung Abnormalities trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Boehringer Ingelheim sponsors the most Interstitial Lung Abnormalities trials on record, review their full trial history before evaluating a specific study. See Boehringer Ingelheim's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Interstitial Lung Abnormalities condition card totals 1 registered trials; most-linked intervention Nerandomilast; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.